CB vs CBIO · P/E 14, rev $59.40B vs $491.3M cap
Chubb Ltd (CB) versus Crescent Biopharma, Inc. (CBIO) — a side-by-side from cached financials, not a winner call.
Chubb Ltd (CB) is a insurance - property & casualty company listed on US.
Crescent Biopharma, Inc. (CBIO) is a biotechnology company listed on NASDAQ.
Latest reported CB revenue for 2025-12-31 was $59.40B. Net income was $10.31B. Revenue was up 6.5% from 2024-12-31 to 2025-12-31. CB currently screens at market cap $114.26B and trailing P/E 13.7.
CBIO does not have a complete income-statement cache yet.
CB currently screens at market cap $114.26B and trailing P/E 13.7. CBIO currently screens at market cap $491.3M.
Not investment advice. Open the CB and CBIO stock pages for the full models.
Not investment advice.